BLFS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whe.

RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.

Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen's exposure to one of the faster-growing areas of bioprocessing.

NEW YORK, July 22, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating BioLife Solutions, Inc. (NASDAQ: BLFS ) related to its sale to Repligen Corporation.

MILWAUKEE, July 22, 2026 /PRNewswire/ -- Ademi LLP is investigating BioLife (NASDAQ: BLFS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Repligen. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 billion.

Repligen Corp said on ​Wednesday it would buy ‌BioLife Solutions in a cash-and-stock deal valued at about $1.5 ​billion, to expand the drugmaking ​equipment provider's presence in ⁠the fast-growing cell ​therapy market.

BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2026 first quarter financial results will be released on May 7, 2026.